Abstract
Background
Accumulating studies have shown that cystatin C may play important roles in the pathogenesis of arteriosclerosis. However, the association between serum cystatin C and the characteristics of carotid plaques has not been elucidated. Furthermore, the diagnostic value of serum cystatin C in carotid stenosis has not been studied.
Methods
Serum cystatin C in 156 patients with acute ischemic stroke (AIS) in the carotid artery was measured by ELISA. Intima-media thickness (IMT), stenosis of the symptomatic common carotid artery (CCA), extra/intracranial internal carotid artery (ICA) stenosis, and plaque characteristics were measured and recorded. Receiver operating characteristic (ROC) curves were used to assess the diagnostic value of serum cystatin C in carotid stenosis.
Results
One hundred fifty-six patients were divided into two groups based on their cystatin C levels. The degree of arteriosclerosis, the severity of plaques, and stenosis of the symptomatic CCA were significantly higher in the patients with high cystatin C levels. In addition, the rate of unstable plaques was significantly higher in those with high cystatin C. Serum cystatin C levels of 1.075 and 1.125 mg/L had diagnostic value in distinguishing stenosis of CCA and extracranial ICA, respectively.
Conclusions
Higher cystatin C levels were strongly correlated with symptomatic CCA stenosis and the rate of unstable plaques. Analysis of cystatin C levels may be useful for the identification of CCA stenosis and extracranial ICA in patients with AIS.
Similar content being viewed by others
References
Liu M, Wu B, Wang W-Z, Lee L-M, Zhang S-H, Kong L-Z (2007) Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 6(5):456–464. https://doi.org/10.1016/s1474-4422(07)70004-2
Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, Muller W, Sandmann W, Stoll G (2001) Expression of tissue factor in high-grade carotid artery stenosis - association with plaque destabilization. Stroke 32(4):850–854. https://doi.org/10.1161/01.str.32.4.850
Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ (2001) Primary prevention of ischemic stroke - a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 103(1):163–182
Hillen T, Nieczaj R, Munzberg H, Schaub R, Borchelt M, Steinhagen-Thiessen E (2000) Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: the Berlin Ageing Study. J Intern Med 247(6):679–688. https://doi.org/10.1046/j.1365-2796.2000.00681.x
He X-W, Ke S-F, Bao Y-Y, Hong W-J, Shen Y-G, Li C, Zhu F, Wang E, Jin X-P (2018) Serum levels of endocan and endoglin are associated with large-artery atherosclerotic stroke. Clin Chim Acta 478:157–161. https://doi.org/10.1016/j.cca.2017.1.2.940
Wu W, Guan Y, Xu K, Fu X-J, Lei X-F, Lei L-J, Zhang Z-Q, Cheng Y, Li Y-Q (2016) Plasma Homocysteine levels predict the risk of acute cerebral infarction in patients with carotid artery lesions. Mol Neurobiol 53(4):2510–2517. https://doi.org/10.1007/s12035-015-9226-y
Xu Z, Leng C, Yang B, Wang H, Sun J, Liu Z, Yang L, Ge W, Zhu J (2017) Serum cystatin C is associated with large cerebral artery stenosis in acute ischemic stroke. Oncotarget 8(40):67181–67188. https://doi.org/10.18632/oncotarget.18061
Zhang Y, Sun L (2017) Cystatin C in cerebrovascular disorders. Curr Neurovasc Res 14(4):406–414. https://doi.org/10.2174/1567202614666171116102504
Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw D, Curhan GC, De Jong PE (2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65(4):1416–1421. https://doi.org/10.1111/j.1523-1755.2004.00517.x
Doganer YC, Aydogan U, Aparci M, Nerkiz P, Barcin C, Cayci T, Sari O (2014) Comparison of cystatin-C and pentraxin-3 in coronary atherosclerosis. Coron Artery Dis 25(7):589–594. https://doi.org/10.1097/mca.0000000000000132
Longenecker CT, Hileman CO, Funderburg NT, McComsey GA (2014) Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV Trial. Clin Infect Dis 59(8):1148–1156. https://doi.org/10.1093/cid/ciu523
(1989) Stroke--1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 20(10):1407–1431
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1):35–41
Schumacher HC, Meyers PM, Higashida RT, Derdeyn CP, Lavine SD, Nesbit GM, Sacks D, Rasmussen P, Wechsler LR (2010) Reporting standards for angioplasty and stent-assisted angioplasty for intracranial atherosclerosis (reprinted from Stroke 2009, VOL 40, PG 348-365). J Neurointerv Surg 2(4):324–340. https://doi.org/10.1136/jnis.2010.002345
Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KEJ, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT (2003) From vulnerable plaque to vulnerable patient - a call for new definitions and risk assessment strategies: part I. Circulation 108(14):1664–1672. https://doi.org/10.1161/01.cir.0000087480.94275.97
Sztajzel R (2005) Ultrasonographic assessment of the morphological characteristics of the carotid plaque. Swiss Med Wkly 135(43–44):635–643
MRC European Carotid Surgery Trial (1991) Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists’ Collaborative Group. Lancet (London, England) 337(8752):1235–1243. https://doi.org/10.1016/0140-6736(91)92916-p
Ebesunun MO, Obajobi EO (2012) Elevated plasma homocysteine in type 2 diabetes mellitus: a risk factor for cardiovascular diseases. Pan Afr Med J 12:48
Seliger SL, Longstreth WT, Katz R, Manolio T, Fried LF, Shlipak M, Stehman-Breen CO, Newman A, Sarnak M, Gillen DL, Bleyer A, Siscovick DS (2005) Cystatin C and subclinical brain infarction. J Am Soc Nephrol 16(12):3721–3727. https://doi.org/10.1681/asn.2005010006
Sukhova GK, Wang B, Libby P, Pan JH, Zhang Y, Grubb A, Fang K, Chapman HA, Shi GP (2005) Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 96(3):368–375. https://doi.org/10.1161/01.res.0000155964.34150.f7
Panayiotou AG, Griffin MB, Tyllis T, Georgiou N, Bond D, Humphries SE, Nicolaides AN (2013) Association of genotypes at the matrix metalloproteinase (MMP) loci with carotid IMT and presence of carotid and femoral atherosclerotic plaques. Vasc Med 18(5):298–306. https://doi.org/10.1177/1358863x13502698
Correa S, Morrow DA, Braunwald E, Davies RY, Goodrich EL, Murphy SA, Cannon CP, O'Donoghue ML (2018) Cystatin C for risk stratification in patients after an acute coronary syndrome. J Am Heart Assoc 7(20):e009077. https://doi.org/10.1161/jaha.118.009077
Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, Frankel M, Chimowitz MI, Grp WS (2007) Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 69(22):2063–2068. https://doi.org/10.1212/01.wnl.0000279338.18776.26
Ferguson TW, Komenda P, Tangri N (2015) Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens 24(3):295–300. https://doi.org/10.1097/mnh.0000000000000115
Pottel H, Delanaye P, Schaeffner E, Dubourg L, Eriksen BO, Melsom T, Lamb EJ, Rule AD, Turner ST, Glassock RJ, De Souza V, Selistre L, Goffin K, Pauwels S, Mariat C, Flamant M, Ebert N (2017) Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C. Nephrol Dial Transplant 32(3):497–507. https://doi.org/10.1093/ndt/gfw425
Betge S, Kretzschmar D, Figulla HR, Lichtenauer M, Jung C (2017) Predictive value of the augmentation index derived vascular age in patients with newly diagnosed atherosclerosis. Heart Vessel 32(3):252–259. https://doi.org/10.1007/s00380-016-0868-0
Umemura T, Kawamura T, Mashita S, Kameyama T, Sobue G (2016) Higher levels of cystatin C are associated with extracranial carotid artery steno-occlusive disease in patients with noncardioembolic ischemic stroke. Cerebrovasc Dis Extra 6(1):1–11. https://doi.org/10.1159/000443338
Kataoka H (2009) Cathepsin enzymes and cystatin C: do they play a role in positive arterial remodeling? Response. Stroke 40(2):E28. https://doi.org/10.1161/strokeaha.108.538553
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study conformed to Ethical Guidelines for Medical and Health Research Involving Human Subjects endorsed by the Chinese government.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ren, J., Dong, X. & Nao, J. Serum cystatin C is associated with carotid atherosclerosis in patients with acute ischemic stroke. Neurol Sci 41, 2793–2800 (2020). https://doi.org/10.1007/s10072-020-04383-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-020-04383-9